PCRX

Pacira BiosciencesB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$34.00

+52.8% vs current

Most likely

Base case

45%

Probability

Target price

$28.00

+25.8% vs current

B-

Bear case

30%

Probability

Target price

$17.00

-23.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

Primary-source evidence improved meaningfully with the April 30, 2026 earnings release and 10-Q, but delayed analyst revision coverage remained thin in the checked sources. The immediate post-earnings tape was not unequivocally bullish: PCRX closed at $24.44 on May 1, 2026 after a volatile session, so the market appears to be weighing reiterated guidance and portfolio growth against margin, tariff, and execution questions. With low coverage and a catalyst set that is still mostly ahead of the company, this remains a monitoring-style neutral setup rather than a high-conviction post-earnings turn.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-30catalystQ1 earnings digestion after guidance reiterationMedium impact

Pacira reported Q1 2026 revenue of $177.4 million, non-GAAP net income of $24.5 million, adjusted EBITDA of $40.2 million, and reiterated FY2026 total revenue guidance of $745 million to $770 million; the first full post-print session closed at $24.44 on May 1 after a volatile day, suggesting investors want cleaner margin and cash-flow follow-through before rerating [#8-K-2026-04-30].

2026-12-31eventZILRETTA shoulder Phase 3 topline later in 2026High impact

The company completed enrollment in its Phase 3 registrational study of ZILRETTA for osteoarthritis pain of the shoulder in April 2026 and said topline results are expected by year-end; success could support the first on-label shoulder OA indication for the product [#8-K-2026-04-30].

2026-12-31catalystPCRX-201 ASCEND readout can validate the HCAd platformHigh impact

Pacira said it completed Part A enrollment in the Phase 2 ASCEND study of PCRX-201 in knee osteoarthritis, expects to initiate Part B around mid-2026, and expects Part A topline results before the end of 2026; a clean readout would matter beyond one asset because PCRX-201 is the lead program from the company’s HCAd platform [#10-Q-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology